UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/536,716	05/30/2006	Catherine Verfaillie	890003-2003.1	2211
27805 THOMPSON H	7590 01/13/200 IINE L.L.P.	9	EXAM	INER
Intellectual Prop	perty Group		QIAN, CELINE X	
P.O. BOX 8801 DAYTON, OH			ART UNIT	PAPER NUMBER
			1636	
			MAIL DATE	DELIVERY MODE
			01/13/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Commons	10/536,716	VERFAILLIE ET AL.				
Office Action Summary	Examiner	Art Unit				
	CELINE X. QIAN	1636				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. nely filed the mailing date of this co D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
	- action is non-final.					
3) Since this application is in condition for allowan						
closed in accordance with the practice under E	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-20 are subject to restriction and/or e	lection requirement.					
Application Papers						
	•					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
	11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119	animon rete the attached office	, totion of form 1	0 102.			
<u> </u>		(1)				
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	⊢(a) or (t).				
a) All b) Some * c) None of:	have been received					
1. Certified copies of the priority documents		an Na				
2. Certified copies of the priority documents		·	Cha sua			
3. Copies of the certified copies of the prior	•	o in this National	Stage			
	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal Pa					
Paper No(s)/Mail Date	6) Other:	. ,				

DETAILED ACTION

Page 2

Claims 1-20 are pending in the application.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-8, 20, drawn to a method of altering a first gene expression pattern in an isolated multipotent adult progenitor cell (MAPC) comprising: introducing into a MAPC an exogenous polynucleotide molecule that comprises a targeting polynucleotide sequence homologous to a genomic DNA sequence of the MAPC and a donor sequence of interest, and culturing the MAPC under conditions to homologously recombine the exogenous polynucleotide molecule such a resultant MAPC has a second expression pattern different than the first gene expression pattern.

Group II, claims 9, 18 and 19, drawn to genetically altered MAPC comprising an exogenous polynucleotide homologously recombined into the genome of a MAPC and a differentiated cell arising from said MAPC.

Group III, claims 10-17, drawn to a method of correcting a genetic defect in a mammal, comprising culturing a MAPC from the mammal, introducing into a MAPC an exogenous polynucleotide molecule that comprises a targeting polynucleotide sequence homologous to a genomic DNA sequence of the MAPC and a donor sequence necessary for correcting said genetic defect, culturing the MAPC under conditions to homologously recombine the exogenous polynucleotide molecule, selecting said MAPC and transplanting said genetically altered MAPC into the mammal.

PCT Rule 13.2 requires that unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as Groups I-III do not relate to a single general inventive concept because they lack the same or corresponding special technical feature. The "special technical feature" of Group I is a MAPC

comprising an exogenously incorporated sequence, which is shown by Hatada et al (PNAS, December 2000. Vol.97, No.25, pages 13807-13811, see page 13809, 1st col., 2nd paragraph, and Figure 2) to lack novelty or inventive step over the disclosed hematopoietic stem cells comprising HPRT, and does not make a contribution over the prior art. As such, this technical feature cannot link the invention as a whole to form a single general inventive concept under PCT Rule 13.1.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected

Art Unit: 1636

process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELINE X. QIAN whose telephone number is (571)272-0777. The examiner can normally be reached on 10-6:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/536,716 Page 5

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Celine X Qian / Primary Examiner, Art Unit 1636